Red Light Holland (TRIP) Q3 2026 earnings summary

Executive summary

• Revenue increased 8.3% year-over-year to $1.265M in Q3 2026, with sales rebounding 67.7% sequentially from the previous quarter.

• Gross profit declined 13.7% year-over-year to $0.358M, while G&A expenses fell 15.8% due to lower consulting, management, and legal fees.

• Strategic focus shifted toward R&D and streamlining operations, including ceasing shiitake mushroom production in New Brunswick.

• Management is actively evaluating M&A opportunities to strengthen R&D initiatives.

Financial highlights

• Cash balance at $9.238M as of December 31, 2025, down from $10.226M at September 30, 2025.

• Net use of cash was $0.989M in Q3 2026, compared to a net cash increase of $0.504M in Q3 2025.

• Adjusted EBITDA loss increased 4.5% year-over-year to $0.711M.

• Total assets stood at $18.2M at quarter-end.

• Excess cash invested in Bitcoin ETFs and high-interest savings vehicles.

Outlook and guidance

• Management prioritizes targeted R&D initiatives in psilocybin to drive long-term value.

• Ongoing evaluation of strategic opportunities and disciplined capital allocation.

• Company remains well-capitalized and positioned for responsible growth as global psilocybin opportunities expand.